Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, ...

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns, ...

The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new ...

Novo Nordisk is reshaping its strategy around obesity and diabetes, CEO Maziar Mike Doustdar said at the 44 th Annual J.P.

Patients also have to deal with changes to their health insurance at the start of a new year, and more employers have ...

The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists ...

Disc Medicine (IRON) stock and Sanofi (SNY) stock are in focus as the FDA delays reviews of their drugs selected for National Priority Review vouchers. Read more here.

Why Big Pharma Is Betting Billions To Beat A $170B Patent Cliff. Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 14, 2026 /PRNewswire/ -- Equity-Insider News Commentary – The precisio ...

Wegovy and Zepbound are two FDA-approved weight loss drugs. Learn how they compare in benefits, side effects, and more to ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...